YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Evaluation of Antifungal Activities and Safeties of 6-(3,4-Dichlorophenyl)amino-7chloro-5,8-quinolinedione

6-(3,4-디클로로페닐)아미노-7-클로로-5,8퀴놀린디온의 항진균작용 및 안전성 평가

  • Published : 1998.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

6-(3,4-Dichlorophenyl)amino-7-chloro-5,8-quinolinedione (RCK50) was tested for antifungal activities in mice systemically infected with Candida albicans. The therapeutic potential of RCK50 was also assessed in comparison with ketoconazole. CK50 had $ED_{50}$ 0.22${\pm}$0.01mg/kg. Ketoconazole as a positive control had $ED_{50}$ 6.00${\pm}$1.70mg/kg. Intraperitoneally administered RCK50 at the $ED_{50}$ for 7 days and 14 days reduced Candida albicans colony count in the kidneys and liver. And administered RCK50 at the $ED_{50}$ for 14 days improved survival rates. The genotoxicities of RCK50 had been evaluated. RCK50 was negative in Ames test with Salmonella typhimurium and chromosomal aberration test in CHL cells. RCK50 did not show any clastogenic effect in mouse peripheral blood and was negative in mouse micronucleus assay. These results indicate that RCK50 has no genotoxic potential under these experimental conditions. Acute oral toxicity studies of RCK50 were carried out in ICR mice of both sexes. RCK50 did not show acute oral toxicities and $LD_{50}$ values were over 2,850mg/kg in ICR mice.

Keywords

References

  1. Science v.264 Human mycoses-Drugs and targets for emerging pathogens. Georgopapadakou, N. H.;walsh, J.
  2. New Approaches for antifungal Drugs The need for new antifungal Drugs. Fernandes, P. B.(Eds.) Clark, A. C.
  3. J. Med. Chem. v.14 5,8-Quinolinequinone analogs which inhibit mitochondrial succinoxidase. Bowman, C. M.;Porter, T. H.;Skelton, F. S.;Folkers, K.
  4. Arch. Pharm. Res. v.17 no.3 The synthesis of 6-(N-arylamino)-7-chloro-5,8-quinolinedione derivatives for evaluation of antifungal activities. Ryu, C. K.;Kim, H. J.
  5. Yakhak Hoeji v.39 no.4 The evaluation of in vivo antifungal activities and toxicities of 6-[(N-4-chlorophenyl) amino]-7-chloro-5,8-quinolinediones. Ryu, C. K.;Kim, D. H.;Yun, Y. P.;Heo, M. Y.;Lee, B. M.;Jang, S. J.;Kim, H. J.;Park, Y. M.
  6. Yakhak Hoeji v.40 no.1 The evaluation of in vivo antifungal activities of 6-[(N-4-fluoro)amino]-7-chloro-5,8-quinolinediones. Park, Y. M.;Kim, H. J.;Kim, D. H.;Lee, I. K.;Ryu, C. K.
  7. Yakhak Hoeji v.40 no.5 The evaluation of antifungal activities and safeties of 6-(N-3,4-difluorophenyl)amino]-7-chloro-5,8-quinolinedione Ryu, C. K.;Kim, D. H.;Yun, Y. P.;Heo, M. Y.;Chung, H. M.;Kwon, S. M.;Chung, S. H.
  8. Arch. Pharm. Res. v.20 no.6 In vitro and in vivo antifungal activities of 6-[(N-4-bromo)amino]-7-chloro-5,8-quinolinedione. Ryu, C. K.;Kim, D. H.;Kwon, S. M.;Jung, S. H.;Kim, S. J.
  9. Antimicrobial Agents and Chemother. v.33 no.7 Fluconazole treatment of candidiasis in normal and diabetic rats. Fisher, M. A.;Lee, P. G.;Tarry, W. F.
  10. B. Antimicrobial Agents and Chemother. v.38 no.2 Saperconazole therapy of murine disseminated candidiasis-Efficacy and interaction with amphotericin Sugar, A. M.;Salibian, M.;Goldani, L. Z.
  11. Mutation Res. v.113 Revised methods for the Salmonella mutagenicity test. Maron, D. M.;Ames, B. N.
  12. Mutgenicity Data interpretation guides (DIGs) (Provisional). DIG18 OECD
  13. Progress in Mutation Research v.5 Tests for the induction of chromosomal aberrations and sister chromatid exchanges in cultured Chinese hamster ovary cells. D. K. Gulati;P. S. Sabharwaland;M. D. Shelby
  14. American Type Culture Collection ATCC quality control methods for cell lines.(2nd ed.) Hay, R. J.;Caputo, J.;Macy, M. L.
  15. Mutation Res. v.120 An application of acridine orange fluorescent staining to the micronucleus test. Hayashi, M.
  16. Scientist Tokyo The micronucleus test. Hayashi, M.
  17. Arch. Toxicol. v.54 A new approach to practical toxicity testing. Lorke, D.
  18. Arch. Toxicol. v.47 Significance of the $LD_{50}$-test for toxicological evaluation of chemical substances. Zbinden, G.;Flury-Roversi, M.